Literature DB >> 11897602

In vitro activities of peptide deformylase inhibitors against gram-positive pathogens.

R Wise1, J M Andrews, J Ashby.   

Abstract

The activities of six peptide deformylase (PDF) inhibitors against 107 respiratory tract pathogens were studied and compared to those of ciprofloxacin and amoxicillin-clavulanate. Against Streptococcus pneumoniae, BB-83698 and BB-83815 were the most active PDF inhibitors (MIC at which 90% of the organisms tested were inhibited [MIC(90)], 0.25 microg/ml). Five of the agents showed similar activity against Moraxella catarrhalis (MIC(90), 0.12 microg/ml). All PDF inhibitors were less active against Haemophilus influenzae; BB-3497 was the most active agent (MIC(90), 2 microg/ml). Five agents were studied against Chlamydia spp. and showed activity similar to that of ciprofloxacin (MIC, 0.5 to 4 microg/ml). This study demonstrates that PDF inhibitors have the potential to be developed for the treatment of respiratory tract infections.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11897602      PMCID: PMC127088          DOI: 10.1128/AAC.46.4.1117-1118.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor.

Authors:  J M Clements; R P Beckett; A Brown; G Catlin; M Lobell; S Palan; W Thomas; M Whittaker; S Wood; S Salama; P J Baker; H F Rodgers; V Barynin; D W Rice; M G Hunter
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Commercially available fluorescein-conjugated monoclonal antibody for determining the in vitro activity of antimicrobial agents against Chlamydia trachomatis.

Authors:  J M Webberley; R S Matthews; J M Andrews; R Wise
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

3.  The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone.

Authors:  R Wise; J M Andrews
Journal:  J Antimicrob Chemother       Date:  1999-11       Impact factor: 5.790

  3 in total
  8 in total

1.  In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae.

Authors:  Patricia M Roblin; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor.

Authors:  Sandhya Ramanathan-Girish; Juliet McColm; John M Clements; Phil Taupin; Sue Barrowcliffe; John Hevizi; Sharon Safrin; Clive Moore; Gary Patou; Heinz Moser; Alison Gadd; Ute Hoch; Vernon Jiang; Denene Lofland; Kirk W Johnson
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

3.  Role of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus influenzae to the novel peptide deformylase inhibitor LBM415.

Authors:  Charles R Dean; Shubha Narayan; Denis M Daigle; JoAnn L Dzink-Fox; Xiaoling Puyang; Kathryn R Bracken; Karl E Dean; Beat Weidmann; Zhengyu Yuan; Rakesh Jain; Neil S Ryder
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.

Authors:  Thomas R Fritsche; Helio S Sader; Roy Cleeland; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  An improved crystal form of Plasmodium falciparum peptide deformylase.

Authors:  Mark A Robien; Kiet T Nguyen; Abhinav Kumar; Irwin Hirsh; Stewart Turley; Dehua Pei; Wim G J Hol
Journal:  Protein Sci       Date:  2004-03-09       Impact factor: 6.725

6.  Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia.

Authors:  E Azoulay-Dupuis; J Mohler; J P Bédos
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

7.  Non-coding nucleotides and amino acids near the active site regulate peptide deformylase expression and inhibitor susceptibility in Chlamydia trachomatis.

Authors:  Xiaofeng Bao; Niseema D Pachikara; Christopher B Oey; Amit Balakrishnan; Lars F Westblade; Ming Tan; Theodore Chase; Bryce E Nickels; Huizhou Fan
Journal:  Microbiology (Reading)       Date:  2011-06-30       Impact factor: 2.777

8.  Drug forecast - the peptide deformylase inhibitors as antibacterial agents.

Authors:  David R P Guay
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.